Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Corvus Pharmaceuticals, Inc.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed or refractory myeloma.
Must have been exposed to at least 2 cycles of an IMiD containing regimen and PI containing regimen and must be refractory to at least one of the two.
Must have completed and tolerated 2 cycles of daratumumab or other anti-CD38 targeting antibodies.
Active myeloma requiring systemic treatment.
Measurable disease per protocol.
ECOG performance status of 0 - 2.
Life expectancy of at least 3 months.
You may not be if
POEMS syndrome; non-secretory myeloma (no measurable protein on sFLC assay); amyloidosis.
History of select prior malignancies.
Previous intolerance to daratumumab or any study drug.
Received an allogeneic stem cell transplant within 12 months, or an autologous stem cell transplant within 6 months, or have ongoing toxicity related to transplant.
Have an active infection or serious comorbid medical condition.
Any live attenuated vaccination against infectious diseases (e.g., influenza, varicella) within 4 weeks of initiation of study treatment; uncontrolled human immunodeficiency virus, or positive tests for hepatitis B or hepatitis C.
Female participants pregnant or breast-feeding.
Screening chemistry and blood counts within protocol limits
Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment or anticipation of need for systemic immunosuppressant medication during study treatment.
Clareo Health | Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma
